Stabilized immunomodulatory oligonucleotides

US8008267B2 · kind B2 · utility

Assignee

• IDERA PHARMACEUTICALS, INC. · US

Inventors

• Ekambar Kandimalla · Upton, US
• Lakshmi Bhagat · Framingham, US
• Rajendra K. Pandey · Foster City, US
• Dong Yu · Lowell, US
• Sudhir Agrawal · Shrewsbury, US

Key dates

• Filing date: Jun 10, 2004
• Grant date: Aug 30, 2011
• Expiry date: Apr 2, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2320/51
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides immunostimulatory oligonucleotides having at least one CpG dinucleotide and a secondary structure at the 5′- or 3′-end. These oligonucleotides have either reduced or improved immunostimulatory properties. The invention establishes that 5′-terminal secondary structures affect immunostimulatory activity significantly more than those at the 3′-end. The invention also provides methods for increasing or decreasing the immunostimulatory activity of a CpG-containing nucleic acid.